Effects of gabexate mesilate on serum inflammatory cytokines in rats with acute necrotizing pancreatitis

被引:28
作者
Chen, CC
Wang, SS
Tsay, SH
Lee, FY
Lu, RH
Chang, FY
Lee, SD
机构
[1] Vet Gen Hosp, Dept Med, Div Gastroenterol, Taipei 112, Taiwan
[2] Vet Gen Hosp, Dept Pathol, Taipei 112, Taiwan
[3] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan
关键词
acute pancreatitis; gabexate mesilate; interleukin-6; interleukin-10; tumor necrosis factor alpha;
D O I
10.1016/j.cyto.2005.12.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Gabexate mesilate is a synthetic protease inhibitor. The effectiveness of gabexate mesilate in patients with acute pancreatitis is controversial. Proinflammatory cytokines are associated with systemic inflammatory response syndrome (SIRS) in acute pancreatitis. A compensatory anti-inflammatory response occurs in parallel with SIRS. We investigated the effects of gabexate mesilate on acute necrotizing pancreatitis in rats, emphasizing the changes in serum levels of proinflammatory and anti-inflammatory cytokines. Acute necrotizing pancreatitis was induced by retrograde infusion of sodium taurodeoxycholate into the pancreatobiliary duct in rats. The rats were divided into three groups. Group I was given gabexate mesilate 2 mg/kg/h i.v. continuously I It before the induction of acute pancreatitis. Group 11 was given gabexate mesilate the same dose immediately after the induction of acute pancreatitis. Group III was given normal saline as the controls. Serum levels of amylase, lipase, tumor necrosis factor alpha., interleukin-6, and interleukin-10, pancreatic histopathology and hemodynamics were examined at 5 h after the induction of acute pancreatitis. Gabexate mesilate significantly reduced serum levels of amylase, lipase, tumor necrosis factor U. and interleukin-6 at 5 h. Serum levels of interleukin-10 significantly increased in Group I, as compared with Groups II and III. The severity of pancreatic histopathology, the reduction of mean arterial pressure, the volume of ascites and pancreatic wet weight/body weight ratios were also significantly improved by the administration of gabexate mesilate. The beneficial effects of gabexate mesilate on acute pancreatitis may be, in part, due to the modulation of inflammatory cytokine responses. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:95 / 99
页数:5
相关论文
共 26 条
[1]   Prophylaxis of ERCP-Related Pancreatitis: A Randomized, Controlled Trial of Somatostatin and Gabexate Mesylate [J].
Andriulli, Angelo ;
Solmi, Luigi ;
Loperfido, Silvano ;
Leo, Pietro ;
Festa, Virginia ;
Belmonte, Angelo ;
Spirito, Fulvio ;
Silla, Michele ;
Forte, Giovambattista ;
Terruzzi, Vittorio ;
Marenco, Giorgio ;
Ciliberto, Enrico ;
Sabatino, Antonio ;
Monica, Fabio ;
Magnolia, Maria Rita ;
Perri, Francesco .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (08) :713-718
[2]  
Bhatia M, 2000, J PATHOL, V190, P117
[3]  
BUCHLER M, 1993, GASTROENTEROLOGY, V104, P1165
[4]   Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography [J].
Cavallini, G ;
Tittobello, A ;
Frulloni, L ;
Masci, E ;
Mariani, A ;
DiFrancesco, V ;
Angelini, GP ;
Casarini, MB ;
Bedogni, G ;
Conigliaro, R ;
Bonardi, L ;
Khajekini, MTA ;
Cipolletta, L ;
Bianco, MA ;
Costamagna, G ;
Perri, V ;
Dobrilla, G ;
DePretis, G ;
Familiari, L ;
Giacobbe, G ;
Fratton, A ;
Carone, N ;
Loriga, P ;
Muscas, A ;
Mazzeo, F ;
Gaeta, L ;
Miglioli, M ;
Pezzilli, R ;
Morelli, A ;
Santucci, L ;
Naccarato, R ;
DelFavero, G ;
Orlandi, F ;
Macarri, GP ;
Russo, A ;
Virgilio, C ;
Uomo, G ;
Manes, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (13) :919-923
[5]   Serum interleukin 10 and interleukin 11 in patients with acute pancreatitis [J].
Chen, CC ;
Wang, SS ;
Lu, RH ;
Chang, FY ;
Lee, SD .
GUT, 1999, 45 (06) :895-899
[6]   Effects of high dose octreotide on retrograde bile salt-induced pancreatitis in rats [J].
Chen, CC ;
Wang, SS ;
Tsay, SH ;
Lee, FY ;
Wu, SL ;
Lu, RH ;
Chang, FY ;
Lee, SD .
PEPTIDES, 1998, 19 (03) :543-547
[7]  
Chen CC, 1999, AM J GASTROENTEROL, V94, P213
[8]  
Chen HM, 1997, J FORMOS MED ASSOC, V96, P704
[9]  
Dabrowski A, 1994, J Physiol Pharmacol, V45, P455
[10]  
GOEBELL H, 1988, DIGESTION, V40, P83